The target of rapamycin (TOR) is a highly conserved Ser/Thr kinase that plays a central role in the control of cellular growth. TOR has a characteristic multidomain structure. Only the kinase domain has catalytic function; the other domains are assumed to mediate interactions with TOR substrates and regulators. Except for the rapamycin-binding domain, there are no high-resolution structural data available for TOR. Here, we present a structural, biophysical, and mutagenesis study of the extremely conserved COOH-terminal FATC domain. The importance of this domain for TOR function has been highlighted in several publications. We show that the FATC domain, in its oxidized form, exhibits a novel structural motif consisting of an ␣-helix and a COOHterminal disulfide-bonded loop between two completely conserved cysteine residues. Upon reduction, the flexibility of the loop region increases dramatically. The structural data, the redox potential of the disulfide bridge, and the biochemical data of a cysteine to serine mutant indicate that the intracellular redox potential can affect the cellular amount of the TOR protein via the FATC domain. Because the amount of TOR mRNA is not changed, the redox state of the FATC disulfide bond is probably influencing the degradation of TOR.Regulation of cellular growth is a prerequisite for cells, organs, and organisms to achieve a characteristic size. The target of rapamycin (TOR, 1 also known as FRAP, RAFT, RAPT, or SEPT) is a highly conserved 280-kDa Ser/Thr kinase that has been shown to play a central role in the control of cell growth in organisms ranging from yeast to human (1, 2). TOR proteins consist of several functional domains (see Fig. 1a) (3). The amino-terminal ϳ1200 residues consist of stretches of HEAT (huntingtin, elongation factor 3, regulatory subunit A of PP2A, TOR1) repeats, which typically mediate protein-protein interactions. Recently, it was also suggested that the ϳ550-amino acid-long FAT (FRAP, ATM, TTRAP) domain that follows the HEAT repeats is composed of HEAT repeat-like ␣-helical structures and could also serve as a protein interaction platform (4). The known interactions of TOR with other proteins have been reviewed recently (1, 2). The FKBP12-rapamycin binding site is flanked by the FAT domain and the catalytic kinase domain. Binding of the FKBP12⅐rapamycin complex to the FKBP12-rapamycin-binding domain specifically inhibits TOR (5). The catalytic kinase domain is highly homologous to that of phosphatidylinositol 3-and 4-kinases. Thus, TOR and its relatives have been termed phosphatidylinositol kinase-related kinases. TOR has been shown to fulfill its functions by directly phosphorylating serine and threonine residues of target proteins and by regulating protein phosphatases (1, 2). The carboxylterminal ϳ33 residues of TOR form the FATC domain. In all phosphatidylinositol kinase-related kinases, the FATC domain always occurs in tandem with the FAT domain (6). Previous studies have shown that the FATC domain is indispensable for TOR function in vivo and ...